CTI BioPharma (CTIC) PT Raised to $12 at Brookline Capital Markets Following FDA Approval
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Wall St rebounds after Fed's first rate hike in years as oil, Treasury yields dip
- Oil falls 2% to one-week low as Middle East supply disruption fears ease
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- Paradium AI (PAAI) Halted, News Pending
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
Increasing unusual option volume: MULN EQNR APLS WEAT CTIC
March 1, 2022 9:53 AM ESTIncreasing unusual option volume: MULN EQNR APLS WEAT CTIC
... MorePre-Open Stock Movers 03/01: (CTIC) (TGT) (DDD) Higher; (GDRX) (VRM) (AMBA) Lower (more...)
March 1, 2022 9:27 AM ESTPre-Open Stock Movers:
CTI BioPharma Corp. (Nasdaq: CTIC) 54% HIGHER; announced the U.S. Food and Drug Administration (FDA) has approved VONJO (pacritinib) for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 Ã-109/L. VONJO is a novel oral kinase inhibitor with specificity for JAK2 and IRAK1, without inhibiting JAK1. The recommended dosage of VONJO is 200 mg orally twice daily. VONJO is the... More
CTI BioPharma (CTIC) Climbs 37% Following Accelerated FDA Approval of VONJO
March 1, 2022 7:17 AM ESTCTI BioPharma (NASDAQ: CTIC) Climbs 37% Following Accelerated FDA Approval of VONJO
... MoreStifel Reiterates Buy Rating on CTI BioPharma (CTIC), Expects Stock to Trade Up Substantially on Vonjo Approval
March 1, 2022 6:41 AM ESTStifel analyst Benjamin Burnett reiterated a Buy rating on CTI BioPharma (NASDAQ: CTIC), following approval of the company's Vonjo drug.
The analyst quotes: "We reiterate our Buy rating on CTIC following the approval of Vonjo (pacritinib) for the treatment of myelofibrosis patients with severe thrombocytopenia.... More
CTI BioPharma (CTIC) Granted FDA Accelerated Approval of VONJO
March 1, 2022 6:01 AM ESTCTI BioPharma Corp. (Nasdaq: CTIC) today announced the U.S. Food and Drug Administration (FDA) has approved VONJO (pacritinib) for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 109/L. VONJO is a novel oral kinase inhibitor with specificity for JAK2 and IRAK1, without inhibiting JAK1. The recommended dosage of VONJO is 200 mg orally twice daily. VONJO is the first approved therapy that specifically addresses the needs of patients with cytopenic myelofibrosis.
"Today's approval of VONJO establishes a new standard of... More
